Abstract
Ovarian cancer (OC) is a highly malignant tumor. X inactive specific transcript (XIST) was identified as a cancer-related gene, while its therapeutic effect in OC was poorly defined. The present study was designed to investigate the effectual corollary of the lncRNA XIST in OC. RT-qPCR was used to detect the XIST and miR-106a expression levels of OC tissues and cell lines. OC cell apoptosis and proliferation were detected by flow cytometry, colony formation, and CCK-8 assays. Moreover, bioinformatics analysis was used to predict the targeted miRNA of XIST. The dual-luciferase reporter and RNA pull-down assays were then used to verify the interaction between miR-106a and XIST. OC xenograft nude mice were raised to measure tumor growth. Notably, OC tissues and cells exhibited low XIST levels and high miR-106a levels. The XIST upregulation decreased the OVCAR3 and CAOV3 cell proliferation and inversely promoted cell apoptosis. miR-106a targeted the XIST. Also, the miR-106a overexpression reversed the inhibitory effects of XIST on OC cell proliferation and apoptosis. Our in vivo results suggested that XIST was involved in tumor growth deceleration, while the miR-106a reversed the effect. To conclusion, the present study demonstrated that XIST suppressed OC development via sponging miR-106a both in vitro and in vivo.
Similar content being viewed by others
Data accessibility
The datasets used during the current study are available from the corresponding author on a reasonable request.
References
Cunnea P, Gowers S, Moore JE Jr, Drakakis E, Boutelle M, Fotopoulou C. Review article: novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer. Converg Sci Phys Oncol. 2017. https://doi.org/10.1088/2057-1739/aa5cf1.
Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014;6:229–39.
Armbruster S, Coleman RL, Rauh-Hain JA. Management and treatment of recurrent epithelial ovarian cancer. Hematol Oncol Clin N Am. 2018;32:965–82.
Schmid BC, Oehler MK. New perspectives in ovarian cancer treatment. Maturitas. 2014;77:128–36.
Feng W, Marquez RT, Lu Z, et al. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer. 2008;112:1489–502.
Ratner E, Lu L, Boeke M, et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res. 2010;70:6509–15.
Zhang L, Ma T, Brozick J, et al. Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer. Oncogene. 2016;35:5010–20.
Scott MS, Ono M. From snoRNA to miRNA: dual function regulatory non-coding RNAs. Biochimie. 2011;93:1987–92.
Zhu J, Kong F, **ng L, ** Z, Li Z. Prognostic and clinicopathological value of long noncoding RNA XIST in cancer. Clin Chim Acta. 2018;479:43–7.
Du Y, Weng XD, Wang L, et al. LncRNA XIST acts as a tumor suppressor in prostate cancer through sponging miR-23a to modulate RKIP expression. Oncotarget. 2017;8:94358–70.
Gao W, Gao J, Chen L, Ren Y, Ma J. Targeting XIST induced apoptosis of human osteosarcoma cells by activation of NF-kB/PUMA signal. Bioengineered. 2019;10:261–70.
Hu Y, Mei XQ, Tang D. Long non-coding RNA XIST is down-regulated and correlated to better prognosis in ovarian cancer. Math Biosci Eng. 2020;17:2070–81.
Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK. miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov. 2016;6:235–46.
Cai ZH, Chen LM, Liang YJ, et al. Experimental study on the inhibition effect of miR-106a inhibitor on tumor growth of ovarian cancer xenografts mice. Asian Pac J Trop Med. 2016;9:698–701.
Wang C, Qi S, **e C, Li C, Wang P, Liu D. Upregulation of long non-coding RNA XIST has anticancer effects on epithelial ovarian cancer cells through inverse downregulation of hsa-miR-214-3p. J Gynecol Oncol. 2018;29:e99.
Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21:1253–61.
Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36:5661–7.
Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. Biochim Biophys Acta. 2014;1839:1097–109.
Zhou Q, Hu W, Zhu W, et al. Long non coding RNA XIST as a prognostic cancer marker—a meta-analysis. Clin Chim Acta. 2018;482:1–7.
Chen DL, Chen LZ, Lu YX, et al. Long noncoding RNA XIST expedites metastasis and modulates epithelial–mesenchymal transition in colorectal cancer. Cell Death Dis. 2017;8:e3011.
Cui CL, Li YN, Cui XY, Wu X. lncRNA XIST promotes the progression of laryngeal squamous cell carcinoma by sponging miR144 to regulate IRS1 expression. Oncol Rep. 2020;43:525–35.
Cheng Z, Luo C, Guo Z. LncRNA-XIST/microRNA-126 sponge mediates cell proliferation and glucose metabolism through the IRS1/PI3K/Akt pathway in glioma. J Cell Biochem. 2020;121:2170–83.
Huang KC, Rao PH, Lau CC, et al. Relationship of XIST expression and responses of ovarian cancer to chemotherapy. Mol Cancer Ther. 2002;1:769–76.
Han Q, Li L, Liang H, Li Y, **e J, Wang Z. Downregulation of lncRNA X inactive specific transcript (XIST) suppresses cell proliferation and enhances radiosensitivity by upregulating mir-29c in nasopharyngeal carcinoma cells. Med Sci Monit. 2017;23:4798–807.
Kong Q, Zhang S, Liang C, et al. LncRNA XIST functions as a molecular sponge of miR-194-5p to regulate MAPK1 expression in hepatocellular carcinoma cell. J Cell Biochem. 2018;119:4458–68.
Li X, Hou L, Yin L, Zhao S. LncRNA XIST interacts with miR-454 to inhibit cells proliferation, epithelial mesenchymal transition and induces apoptosis in triple-negative breast cancer. J Biosci. 2020;45:1–11.
Pan YJ, Zhuang Y, Zheng JN, Pei DS. MiR-106a: promising biomarker for cancer. Bioorg Med Chem Lett. 2016;26:5373–7.
Jiang Y, Wu Y, Greenlee AR, et al. miR-106a-mediated malignant transformation of cells induced by anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide. Toxicol Sci. 2011;119:50–60.
Qin Y, Huo Z, Song X, Chen X, Tian X, Wang X. mir-106a regulates cell proliferation and apoptosis of colon cancer cells through targeting the PTEN/PI3K/AKT signaling pathway. Oncol Lett. 2018;15:3197–201.
Grunewald T, Ledermann JA. Targeted therapies for ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:139–52.
Amini-Farsani Z, Sangtarash MH, Shamsara M, Teimori H. MiR-221/222 promote chemoresistance to cisplatin in ovarian cancer cells by targeting PTEN/PI3K/AKT signaling pathway. Cytotechnology. 2018;70:203–13.
Liu HY, Zhang YY, Zhu BL, et al. MiR-203a-3p regulates the biological behaviors of ovarian cancer cells through mediating the Akt/GSK-3beta/Snail signaling pathway by targeting ATM. J Ovarian Res. 2019;12:60.
Zhou J, Zhang C, Zhou B, Jiang D. miR-183 modulated cell proliferation and apoptosis in ovarian cancer through the TGF-beta/Smad4 signaling pathway. Int J Mol Med. 2019;43:1734–46.
Acknowledgements
This work is financially supported by the National Natural Science Foundation of China (81571797), Natural Science Foundation of Jiangsu, China (BK20151352), Taizhou People’s Hospital Medical Innovation Team Foundation, China (CXTDA201901), and Scientific Research Foundation of Taizhou People’s Hospital (ZL201734/ZL201726), China.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Research involving human/animal participants
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Bioethics Committee of Taizhou People’s Hospital Affiliated to Nantong University (No. 202004701).
Conflict of interest
The authors have no conflicts of interest to declare that are relevant to the content of this article.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Guo, T., Yuan, D., Zhang, W. et al. Upregulation of long noncoding RNA XIST has anticancer effects on ovarian cancer through sponging miR-106a. Human Cell 34, 579–587 (2021). https://doi.org/10.1007/s13577-020-00469-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13577-020-00469-w